Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 2, 2006, Pages 383-392

  Ginsberg, Henry N ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETIC DYSLIPIDEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MYALGIA; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; STROKE; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; MALE;

EID: 32544443164     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-2084     Document Type: Review

References (119)

1. Weitzman S, Wang C, Rosamond WD, Chambless LE, Cooper LS, Shahar E, Goff DC 2004 Is diabetes an independent risk factor for mortality after myocardial infarction? The ARIC (Atherosclerosis Risk in Communities) Surveillance Study. Acta Diabetol 41:77-83
2. The Expert Panel 1988 Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 148:36-69
3. The Expert Panel 1993 Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269:3015-3023
4. American Diabetes Association 1989 Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 12:573-579
5. Wingard DL, Barrett-Conner E 1995 Heart disease and diabetes. In: Harris MI, ed. Diabetes in America. Chap. 19, 2nd ed. NIH Publication no. 95-1468; 429-448
6. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
7. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A 2000 Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 102:1014-1019
8. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, Scandinavian Simvastatin Survival Study (4S) Group 1997 Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620
9. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E 1998 Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98:2513-2519
10. Heart Protection Study Collaborative Group 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
11. Expert Panel on Detection, Treatment, Evaluation, and Treatment of High Blood Cholesterol in Adults 2002 Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106:3143-3421
12. Yan SF, Ramasamy R, Naka Y, Schmidt A-M 2003 Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159-1169
13. Schmidt A-M, Hori O, Brett J, Yan S-D, Wautier S-D, Stern D 1994 Cellular receptors for advanced glycation endproducts: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14:1521-1528
14. Juhan-Vague I, Alessi M, Vague P 1991 Increased plasma PAI-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462
15. Bierman EL 1992 Atherogenesis in diabetes. Arterioscler Thromb 12:647-656
16. Sowers JR 2003 Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 16(Suppl 11):41-45
17. Orchard TJ 1991 Dyslipoproteinemia and diabetes. Endocrinol Metab Clin North Am 19:361-380
18. Howard BV 1987 Lipoprotein metabolism in diabetes mellitus. J Lipid Res 28:613-628
19. Reaven GM, Chen Y-D 1988 Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 4:639-652
20. Ruotolo G, Howard BV 2002 Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 4:494-500
21. Reaven GM 1988 Role of insulin resistance in human disease. Diabetes 37:1595-1607
22. Ginsberg HN 1991 Lipoprotein physiology in nondiabetic and diabetes states. Diabetes Care 14:839-855
23. Siegel RD, Cupples A, Schaefer EJ, Wilson PWF 1996 Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham Offspring Study. Metabolism 45:1267-1272
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
25. UK Prospective Diabetes Study Group 1997 UKPDS 27: plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20:1683-1687
26. Wagner AM, Jorba O, Rigla M, Bonet R, de Leiva A, Ordonez-Llanos J, Perez A 2003 Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes. Metabolism 52:1576-1578
27. Taskinen MR 2002 Controlling lipid levels in diabetes. Acta Diabetol 39(Suppl 2):S29-S34
28. Kissebah AH, Alfarsi S, Evans DJ, Adams PW 1982 Integrated regulation of very-low-density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 31:217-225
29. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson S-O, Packard C, Taskinen MR 2005 Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 25:1697-1703
30. Ginsberg HN 2000 Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458
31. Davis RA 1999 Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta 1440:1-31
32. Olofsson S-O, Stillemark-Billton P, Asp L 2000 Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med 10:338-345
33. Fisher EA, Ginsberg HN 2002 Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 277:17377-17380
34. Fisher EA, Pan M, Chen X, Wu X, Wang H, Jamil H, Sparks JD, Williams KJ 2001 The triple threat to nascent apolipoprotein B: evidence for multiple, distinct degradative pathways. J Biol Chem 276:27855-27863
35. Kissebah AH, Alfarsi S, Adams PW, Wynn V 1996 Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 12:563-571
36. Barter PJ, Nestel PJ 1973 Precursors of plasma triglyceride fatty acids in obesity. Metabolism 22:779-783
37. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G 1995 Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158-166
38. Zhang Y-L, Hernandez-Ono A, Ko C, Yasunaga K, Huang L-S, Ginsberg HN 2004 Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids, I: differential effects of delivering fatty acids via albumin or remnant-like emulsion particles. J Biol Chem 279:19362-19374
39. Cooper AD 1997 Hepatic uptake of chylomicron remnants. J Lipid Res 38:2173-2192
40. Hellerstein MK 1999 De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr 53(Suppl 1):S53-S65
41. Diraison F, Moulin P, Beylot M 2003 Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 29:478-485
42. Schwarz JM, Linfoot P, Dare D, Aghajanian K 2003 Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming highfat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77:43-50
43. Sparks JD, Sparks CE 1994 Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1215:9-32
44. Lewis GF, Uffelman KD, Szeto LW, Steiner G 1993 Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42:833-842
45. Malmstrom R, Packard CJ, Watson TD, Rannikko S, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR 1997 Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454-1464
46. Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, Le-Tien H, Fantus IG, Lewis GF, Adeli K 2002 Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 277:793-803
47. Bourgeois CS, Wiggins D, Hems R, Gibbons GF 1995 VLDL output by hepatocytes from obese Zucker rats is resistant to the inhibitory effect of insulin. Am J Physiol 269:E208-E215
48. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR 1997 Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454-462
49. Taskinen M-R, Nikkila EA, Kuusi T, Harno K 1982 Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus: relationship to plasma triglyceride metabolism. Diabetologia 22:46-50
50. Ginsberg HN, Illingworth DR 2001 Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 88(Suppl):9H-15H
51. Myerson M, Ngai C, Jones J, Holleran S, Ramakrishnan R, Berglund L, Ginsberg HN 2005 Treatment with high dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J Lipid Res 46:2735-2744
52. Gylling H, Mietiinen TA 1997 Cholesterol absorption, synthesis, and LDL metabolism in NIDDM. Diabetes Care 20:90-95
53. Kissebah AH 1987 Low density lipoprotein metabolism in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 3:619-651
54. Sattar N, Williams K, Sniderman AD, D'Agostino Jr R, Haffner SM 2004 Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 110:2687-2693
55. Austin MA, King MD, Vranizan KM, Krauss RM 1990 Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82:495-506
56. Tall AR 1990 Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest 86:379-384
57. Rashid S, Watanabe T, Sakaue T, Lewis GF 2003 Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36:421-429
58. Golay A, Zech L, Shi M-Z 1987 High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 65:512-518
59. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP 1994 Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 14:1767-1774
60. Proctor SD, Pabla CK, Mamo JC 2000 Arterial intimal retention of proatherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis 149:315-322
61. Gray RS, Robbins DC, Wang W, Yeh JL, Fabsitz RR, Cowan LD, et al 1997 Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol 17:2713-2720
62. Sacks FM, Campos H 2003 Clinical review 163: cardiovascular endocrinology: low density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 88:4525-4532
63. Calabresi L, Gomaraschi M, Franceschini G 2003 Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 23:1724-1731
64. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL 1983 Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 80:4124-4128
65. Vega GL, East C, Grundy SM 1989 Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia: effects of kinetics of apolipoprotein B. Arteriosclerosis 9(Suppl 1):I135-I144
66. Malmendier CL, Lontie JF, Delcroix C, Magot T 1989 Effect of simvastatin on receptor-dependent low density lipoprotein catabolism on normocholesterolemic human volunteers. Atherosclerosis 80:101-109
67. Brown MS, Goldstein JL 1986 A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47
68. Watts GF, Cummings MH, Umpleby M, Quiney JR, Naoumova R, Thompson GR, Sonksen PH 1995 Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 25:559-567
69. Arad Y, Ramakrishnan R, Ginsberg HN 1990 Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 31:567-582
70. Vega GL, Grundy SM 1991 Influence of lovastatin therapy on metabolism of low density lipoprotein in mixed hyperlipidaemia. J Intern Med 230:341-350
71. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ 2002 Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 162:227-244
72. Cortner JA, Bennett MJ, Le NA, Coates PM 1993 The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia. J Inherit Metab Dis 16:127-134
73. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T 2004 Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 45:174-185
74. Cuchel M, Schaefer EJ, Millar JS, Jones PJ, Dolnikowski GG, Vergani C, Lichtenstein AH 1997 Lovastatin decreases de novo cholesterol synthesis and LDL ApoB-100 production rates in combined-hyperlipidemic males. Arterioscler Thromb Vasc Biol 17:1910-1917
75. Parhofer KG, Barrett PH, Dunn J, Schonfeld G 1993 Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. Clin Invest 71:939-946
76. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ 2002 Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164:129-145
77. Aguilar-Salinas CA, Hugh P, Barrett R, Pulai J, Zhu XL, Schonfeld G 1997 A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism: kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler Thromb Vasc Biol 17:72-82
78. Watts GF, Chan DC, Barrett PH, O'Neill FH, Thompson GR 2003 Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord 27:862-865
79. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA 2002 Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 51:2377-2386
80. Watts GF, Barrett PHR, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG 2003 Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52:803-811
81. Ouguerram K, Magot T, Zair Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M 2003 Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther 306:332-337
82. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HAW, CARDS investigators 2003 The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease Atherosclerosis 167:243-255
83. Thompson GR, Naoumova RP, Watts GF 1996 Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 37:439-447
84. Cianflone KM, Yasruel Z, Rodriguez MA, Vas D, Sniderman AD 1990 Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res 31:2045-2055
85. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW 1999 The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology 140:5293-5302
86. Arad Y, Ramakrishnan R, Ginsberg H 1992 Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41:487-493
87. Kasim SE, LeBoeuf RC, Khilnani S, Tallapaka L, Dayananda D, Jen K-LC 1992 Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. J Lipid Res 33:1-7
88. Dixon JL, Shea S, Vuchetich JP, Wysocka E, Sun GY, Sturekk M 2002 Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. J Lipid Res 43:1618-1629
89. Yoshino G, Kazumi T, Kasama T, Iwai M, Iwatani I, Matsuba K, Matsushita M, Baba S 1988 Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats. Atherosclerosis 73:191-195
90. Funatsu T, Goto M, Kakuta H, Suzuki M, Ida M, Nishijima S, Tanaka H, Yasuda S, Miyata K 2002 Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. Biochim Biophys Acta 1580:161-170
91. Roglans N, Sanguino E, Peris C, Alegret M, Vazquez M, Adzet T, Diaz C, Hernandez G, Laguna JC, Sanchez RM 2002 Atorvastatin treatment induced peroxisome proliferator-activated receptor α expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 302:232-239
92. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B 2001 Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 107:1423-1432
93. Garg A, Grundy SM 1988 Lovastatin for lowering cholesterol levels in noninsulin-dependent diabetes mellitus. N Engl J Med 318:81-86
94. Torri A, Sommarriva D, Montalto C, Acquati C, Prandi W 1992 Long-term effects of low-dose simvastatin in hypercholesterolemic type 2 diabetic patients. Curr Ther Res 51:28-36
95. Knopp RH, Frolich JJ 1994 Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia: preliminary report. Am J Cardiol 73:39D-41D
96. Best JD, Nicholson GC, O'Neal DN, Kotowicz MA, Tebbutt NC, Chan K-W, Sanders KM 1996 Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diab Nutr Metab 9:74-80
97. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K 2004 Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 64:137-151
98. Diabetes Atorvastin Lipid Intervention (DALI) Study Group 2001 The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335-1341
99. Betteridge D, Gibson M 2004 Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study. Atherosclerosis 5:107-108
100. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K 1999 Reduced coronary events in simvastatintreated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159:2661-2667
101. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A, LIPID Study Group 2003 Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26:2713-2721
102. Heart Protection Study Collaborative Group 2003 MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
103. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group 2002 Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007
104. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1157
105. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696
106. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators 2005 Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248
107. American Diabetes Association 2004 Position statement: dyslipidemia management in adults with diabetes. Diabetes Care 27(Suppl 1):S68-S71
108. Prisant LM 2004 Clinical trials and lipid guidelines for type II diabetes. J Clin Pharmacol 44:423-430
109. MacMahon M, Kirkpatrick C, Cummings CE, Clayton A, Robinson PJ, Tomiak RH, Liu M, Kush D, Tobert J 2000 A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 10:195-203
110. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G, Incremental Decrease in End Points through Aggressive Lipid Lowering Study Group 2004 Design and baseline characteristics of the incremental decrease in end points through aggressive lipid lowering study. Am J Cardiol 94:720-724
111. Fellström B, Zannad F, Schmieder R, Holdaas H, Jardine A, Armstrong J, Siewert-Delle A 2003 A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events - the AURORA study. Nephrol Dial Transplant 18(Suppl):713 (Abstract W520)
112. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239
113. American Diabetes Association 2005 Standards of medical care in diabetes. Diabetes Care 28:S4-S36
114. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R 2004 Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585-2590
115. Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hartford A, Vega JM, Paolini JF 2004 Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 44:1054-1062
116. Garg A, Grundy SM 1990 Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264:723-726
117. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA 2000 Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284:1263-1270
118. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP, Diabetes Multicenter Research Group 2002 Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162:1568-1576
119. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group 2005 High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEA study: a randomized controlled trial. JAMA 294:2437-2445